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Serum xanthine concentrations as high as 148 mg/L were noted after treatment of a patient with Burkitt's lymphoma who was receiving allopurinol. These markedly abovenormal values for xanthine led to spuriously low values for serum uric acid as measured by the uricase method. Rapid tumor lysis in patients who are receiving allopurinol may lead to marked hyperxanthinemia, which in turn may obscure hyperuricemia in such patients when the uricase method is used for uric acid analysis. In such situations, uric acid concentrations should be measured by the phosphotungstate colorimetric assay.
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Burkitt's lymphoma
Burkitt's lymphoma is a rapidly proliferating tumor characterized by dramatic responses to chemotherapy (1) . The sudden lysis of tumor after chemotherapy of Burkitt's lymphoma may lead to one or more metabolic complications, including hyperkalemia, hyperphosphatemia, hypocalcemia, lactic acidosis, and hyperuricemia (2, 3) . To prevent the development of hyperuricemia and uric acid nephropathy, allopurinol frequently is used in the treatment of this and other neoplastic disorders. Allopurinol acts by inhibiting xanthine oxidase (EC 1.2.3.2), thus preventing conversion of hypoxanthine to uric acid. After it is administered, concentrations of uric acid in the serum decline and concentrations of xanthine and hypoxanthine increase (4 
Methods
Blood samples were centrifuged within 2 h of collection. Serum was stored at -20 #{176}C until analysis. Serum xanthine and hypoxanthine concentrations were determined by liquid chromatography after pre-purification of samples by a modification of the method of Sweetman and Nyhan (8) . Samples were analyzed with a Model 310 "high-pressure" liquid chromatograph (Altex Scientific Incorporated, Berkeley, CA 94710) with use of a dual-wavelength detector (254 and 280 nm) and a RP 18, 4 X 300 mm column (Waters Associates, Milford, MA 01757). Ammonium acetate buffer (10 mmol/L, pH 6.7) was the eluent, at a flow rate of 1.5 mL/min. Concentrations were calculated by comparing the areas under the ultraviolet absorbance curve for known standards with those for unknowns.
Uric acid concentrations were determined with two instruments and methodologies: (a) The Automatic Clinical Analyzer (aca; DuPont Co., Wilmington, DE 19898) determination is a kinetic modification of a uricase method (9) . Uric acid, which absorbs light at 293 nm, is converted by uricase to allantoin, which is nonabsorbing at 293 nm. The change in absorbance at 293 nm due to the disappearance of uric acid is directly proportional to the concentration of uric acid in the serum. (b) The uric acid method used with the Sequential Multiple Analyzer with Computer (SMAC; Technicon Instruments Corp., Tarrytown, NY 10591) is based on reduction of a phosphotungstate complex to a phosphotungstite complex (10) . Sodium tungstate is used as an alkalinizing agent, hydroxylamine being added to intensify the color. The phosphotungstite complex formed is proportional to the uric acid present. The absorbance of the complex is measured at 660 nm.
Serum allopurinol and oxipurinol concentrations were determined as described elsewhere (11) . Allopurinol, oxipurinol, xanthine, and hypoxanthine were purchased fron Calbiochem, La Jolla, CA 92112.
Case Report
A 30-year-old man was admitted to the Pediatric Oncology Branch of the National Cancer Institute with dyspnea, night sweats, fatigue, and early satiety.
Physical examination showed diffuse adenopathy, a 12 X 5 cm mass in the abdomen, masses of 3 x 5 cm and 1 x 2 cm in the chest wall, ascites, and a pleural effusion.
Roentgenograms of the chest revealed hilar and mediastinal adenopathy, and a sonographic study confirmed the presence of the abdominal mass. Biopsy of an inguinal lymph node and The patient was treated with allopurinol (200 mg intravenously every 6 h) for three days and his serum uric acid concentration declined to 51 mg/L as measured by the phosphotungstate assay and 46 mgfL as measured by the uricase assay ( Figure 1) .
The patient then was treated with a single dose (1200 mg per square meter of body surface area) of cyclophosphamide, resulting in rapid tumor lysis that completely resolved his chest masses in two days and the abdominal mass in five days. His lactate dehydrogenase declined to 504 U/L in seven days. However, with this excellent antitumor response the patient developed several metabolic abnormalities, including an increase in serum inorganic phosphorus from 32 to 170 mg/L, a decline in serum calcium from 2.1 to 1.6 mmolfL, and the development of renal failure, with serum urea nitrogen increasing to 640 mg/L, creatinine increasing to 39 mg/L, and renal output decreasing to 120 mL/day. The patient underwent three courses of hemodialysis during the 48-h period after chemotherapy, to help maintain a normal metabolic balance. After chemotherapy, different values for serum uric acid were obtained by the two methods, which gradually began to correlate again five days after chemotherapy (Figure 1) . Four days after chemotherapy, the patient's urine volume increased to 4 L/day and his serum urea nitrogen and creatinine concentrations declined from 580 and 58 mg/L, respectively, on the fourth day after chemotherapy to values of 220 and 19 mg/L one week later. Other metabolic abnormalities also were corrected during this time, and the patient was discharged in good condition 17 days after chemotherapy.
Results
To determine whether increased concentrations of other purines in serum were causing erroneous results for either the phosphotungstate or uricase uric acid measurement, we measured allopurinol, oxipurinol, xanthine, and hypoxanthine concentrations in the patient's serum. Notable concentrations of allopurinol were not found in any serum samples, probably because it is rapidly metabolized to oxipurinol in vivo (serum half-life, 40 mm) (11) . Serum oxipurinol concentrations were Xanthine, mg/L 12.5 58 relatively constant (3-9 mgfL) after chemotherapy, but serum xanthine concentrations increased from 10 to 140 mg/L, and were correlated with the difference between serum uric acid as measured by the phosphotungstate and uricase methods ( Figure 1 ). Hypoxanthine concentrations varied from 18 to 51 mg/L, were generally a third to half the serum xanthine concentrations, and did not correlate with the difference in uric acid values.
To determine which method of uric acid measurement was being affected by the above-normal serum xanthine, we added xanthine, hypoxanthine, and oxipurinol in various concentrations to normal serum and measured the uric acid by the phosphotungstate and uricase methods (Table 1) . Xanthine, but not oxipurinol or hypoxanthine, in concentrations of mg/L significantly lowered the apparent uric acid determination as measured by the uricase method. The phosphotungstate assay was not affected by any of the purines tested.
Discussion
Rapid tumor lysis after chemotherapy treatment of certain types of lymphomas and leukemias may lead to acute metabolic disturbances. Development of hyperuricemia is a wellrecognized complication of treatment of some neoplastic diseases, but the development of hyperxanthinemia in patients receiving allopurinol therapy has rarely been recognized or investigated. Band et al. (6) demonstrated the formation of xanthine stones after treatment of a lymphoma patient who was receiving allopurinol, but measured neither serum nor urinary hypoxanthine concentrations. Ablin et al. (7) described a Burkitt's lymphoma patient receiving allopurinol who developed hyperxanthinemia (concentrations of 60 mgfL in the serum) and renal failure after chemotherapy. The serum xanthine concentrations measured in their patient and in our patient (peak xanthine concentrations of 148 mgIL) are severalfold normal (1-3 mg/L) (12) . Because of its rapid renal clearance (13) , markedly increased serum xanthine concentrations are likely to occur only in the presence of renal failure.
Xanthine is the least soluble of the purines (50 mg/L at pH 5 and 130 mg/L at pH 7); hypoxanthine (1400 mg/L at pH 5 and 1500 mg/L at pH 7) and uric acid (150 mg/L at pH 5 and 2000 mg/L at pH 7) are both more soluble in urine than is xanthine (4). Our patient's nephropathy may have resulted from precipitation of uric acid or calcium phosphate. However, a potential but unproven cause of renal failure in our patient may have been the development of xanthine nephropathy. In addition to being a potential cause of renal failure, hyperxanthinemia in our patient appears to have falsely lowered serum uric acid values as determined with the aca by the uricase method. Uricase acts only on uric acid as a substrate for purine ring cleavage and the uricase method for uric acid analysis is considered to be the most specific method (14) . However, xanthine has been shown in vitro to inhibit uricase with a K of 1 X 10 mol/L (15) . The discrepancy in uric acid values between the two assay methods correlated with the serum xanthine concentrations as shown in Figure 1 . As noted in Table 1 , significant inhibition of uricase was demonstrated for xanthine in concentrations of 50 mg/L or higher, but not hypoxanthine or oxipurinol. In the case report of Albin et al. (7), a discrepancy in uric acid values between the colorimetric and uricase methods was also noted, but its cause was not determined. Because xanthine concentrations in serum seldom exceed 50 mgfL, spuriously low uric acid determinations by the uricase method will be unusual. Nevertheless, as results for our patient demonstrate, xanthine concentrations exceeding 50 mgfL can be found in certain lymphoma patients receiving high doses of allopurinol after rapid tumor lysis, and may cause a spurious depression in serum uric acid values as determined by the uricase assay but do not appear to affect determinations performed by the phosphotungstate assay. This spurious depression may lead to underestimation of the potential for developing uric acid nephropathy. Patients on allopurinol undergoing chemotherapy of rapidly proliferating tumors should be followed for the possible development of xanthine nephropathy and these patients should have uric acid determinations performed by the phosphotungstate assay.
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